These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 10178832)

  • 1. Using pharmaceutical cost analyses for decision making.
    U'Ren NA
    Hosp Cost Manag Account; 1997 Nov; 9(8):1-7. PubMed ID: 10178832
    [No Abstract]   [Full Text] [Related]  

  • 2. Serving patient needs while implementing cost effectiveness programs in health care administration.
    Tootelian DH
    Health Mark Q; 1994; 11(3-4):161-73. PubMed ID: 10137013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics and the formulary decision-making process.
    Bakst A
    Hosp Formul; 1995 Jan; 30(1):42-50. PubMed ID: 10172201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic principles and methods: an introduction for hospital pharmacists.
    Sanchez LA
    Hosp Pharm; 1994 Aug; 29(8):774, 777-9. PubMed ID: 10135744
    [No Abstract]   [Full Text] [Related]  

  • 5. Proposed drug-drug cost effectiveness methodology.
    Gagnon JP; Osterhaus JT
    Drug Intell Clin Pharm; 1987 Feb; 21(2):211-6. PubMed ID: 3103997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic factors in the treatment of acute hypertension.
    Shulkin DJ
    Hosp Formul; 1994 Aug; 29 Suppl 2():S15-20. PubMed ID: 10135742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Where does high-quality research in economic evaluation come from?
    Zhang JX
    Pharmacotherapy; 2009 Jan; 29(1):1-2. PubMed ID: 19113791
    [No Abstract]   [Full Text] [Related]  

  • 8. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Researchers begin linking cost with performance to test new drugs' value.
    Hospitals; 1982 Apr; 56(7):54, 57. PubMed ID: 6800913
    [No Abstract]   [Full Text] [Related]  

  • 10. ASHP technical assistance bulletin on assessing cost-containment strategies for pharmacies in organized health-care settings.
    Am J Hosp Pharm; 1992 Jan; 49(1):155-60. PubMed ID: 1570860
    [No Abstract]   [Full Text] [Related]  

  • 11. How to develop a proactive formulary system.
    Crane VS; Gonzalez ER; Hull BL
    Hosp Formul; 1994 Oct; 29(10):700-2, 704-8, 710. PubMed ID: 10137847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic series: Part I. Pharmacoeconomics and the evaluation of drugs and services.
    McGhan WF
    Hosp Formul; 1993 Apr; 28(4):365-6, 371-3, 377-8. PubMed ID: 10125323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rising cost of pharmaceuticals: a director of pharmacy's perspective.
    Pierpaoli PG
    Am J Hosp Pharm; 1993 Aug; 50(8 Suppl 4):S6-8. PubMed ID: 8213862
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of randomized controlled trials in organizational decision making: a cost-minimization approach.
    Cher DJ; Maclure M
    Am J Manag Care; 2000 Aug; 6(8):894-904. PubMed ID: 11186501
    [No Abstract]   [Full Text] [Related]  

  • 15. DRG management. Many factors affect drug treatment costs.
    Mendenhall S
    Mod Healthc; 1985 Feb; 15(4):98-100. PubMed ID: 10273620
    [No Abstract]   [Full Text] [Related]  

  • 16. Strategic planning for applied pharmacoeconomics programs.
    Wanke LA; Ryan GM
    Pharm Pract Manag Q; 1996 Jan; 15(4):64-74. PubMed ID: 10153846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring the cost of drugs.
    Wittrick A
    Health Serv J; 1987 Jun; 97(5054):678. PubMed ID: 10312121
    [No Abstract]   [Full Text] [Related]  

  • 18. The military health services system model for pharmacoeconomic decision making.
    Ries AJ; Potyk RP; Brier KL; Miller MR; Tornow JJ; Weber MP; Finder SF; Reeves CS
    Med Interface; 1995 May; 8(5):132-7. PubMed ID: 10142786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of therapeutic drug monitoring.
    Gardner DM; Hardy BG
    Can J Hosp Pharm; 1990 Feb; 43(1):7-12, xii. PubMed ID: 10113128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revenue enhancement and cost analysis.
    Suver JD; Cooper JC
    Healthc Exec; 1994; 9(4):41. PubMed ID: 10135158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.